PL2445903T3 - 1,3-Di-podstawione pochodne imidazolidyn-2-onu jako inhibitory CYP 17 - Google Patents
1,3-Di-podstawione pochodne imidazolidyn-2-onu jako inhibitory CYP 17Info
- Publication number
- PL2445903T3 PL2445903T3 PL10730132T PL10730132T PL2445903T3 PL 2445903 T3 PL2445903 T3 PL 2445903T3 PL 10730132 T PL10730132 T PL 10730132T PL 10730132 T PL10730132 T PL 10730132T PL 2445903 T3 PL2445903 T3 PL 2445903T3
- Authority
- PL
- Poland
- Prior art keywords
- cyp
- inhibitors
- derivatives
- disubstituted imidazolidin
- imidazolidin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1500CH2009 | 2009-06-26 | ||
IN2181DE2009 | 2009-10-21 | ||
PCT/EP2010/059029 WO2010149755A1 (en) | 2009-06-26 | 2010-06-24 | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
EP10730132.7A EP2445903B1 (en) | 2009-06-26 | 2010-06-24 | 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2445903T3 true PL2445903T3 (pl) | 2014-08-29 |
Family
ID=42357251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL10730132T PL2445903T3 (pl) | 2009-06-26 | 2010-06-24 | 1,3-Di-podstawione pochodne imidazolidyn-2-onu jako inhibitory CYP 17 |
Country Status (44)
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ597107A (en) | 2009-06-25 | 2013-12-20 | Alkermes Pharma Ireland Ltd | Heterocyclic compounds for the treatment of neurological and psychological disorders |
MX345788B (es) | 2010-08-04 | 2017-02-15 | Pellficure Pharmaceuticals Inc * | Nuevo tratamiento del carcinoma de prostata. |
CN103108871B (zh) * | 2010-09-16 | 2014-09-10 | 诺华股份有限公司 | 17α-羟化酶/C17,20-裂合酶抑制剂 |
WO2012097021A1 (en) | 2011-01-11 | 2012-07-19 | Glaxosmithkline Llc | Combination |
MX359399B (es) * | 2011-04-28 | 2018-09-27 | Novartis Ag | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. |
BR122019001978A8 (pt) * | 2011-08-26 | 2023-01-17 | Meiji Seika Pharma Co Ltd | Método para a produção de agente de controle de praga |
US8969586B2 (en) | 2011-09-27 | 2015-03-03 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
CN102702223A (zh) * | 2012-05-28 | 2012-10-03 | 盛世泰科生物医药技术(苏州)有限公司 | 一种2-溴-4-氯噻吩并[3,2-c]吡啶的制备方法 |
JP2015518888A (ja) | 2012-06-06 | 2015-07-06 | ノバルティス アーゲー | 腫瘍疾患を治療するための17−アルファ−ヒドロキシラーゼ(c17,20−リアーゼ)インヒビターと特定のpi−3kインヒビターとの組み合わせ |
EP2968219B1 (en) | 2013-03-14 | 2019-04-24 | Pellficure Pharmaceuticals, Inc. | Novel therapy for prostate carcinoma |
TW201534586A (zh) | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎cyp17抑制劑/抗雄激素劑 |
JP2016526538A (ja) | 2013-06-20 | 2016-09-05 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 殺ダニ剤及び殺虫剤としてのアリールスルフィド誘導体及びアリールスルホキシド誘導体 |
CA2925374A1 (en) * | 2013-10-01 | 2015-04-09 | Novartis Ag | Combination |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
LT3116909T (lt) | 2014-03-14 | 2020-02-10 | Novartis Ag | Antikūno molekulės prieš lag-3 ir jų panaudojimas |
CA2960750A1 (en) | 2014-09-12 | 2016-03-17 | Pellficure Pharmaceuticals, Inc. | Compositions and methods for treatment of prostate carcinoma |
US9783527B2 (en) * | 2014-09-16 | 2017-10-10 | Abbvie Inc. | Indazole ureas and method of use |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
PE20171067A1 (es) | 2014-10-14 | 2017-07-24 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
US10449211B2 (en) | 2015-03-10 | 2019-10-22 | Aduro Biotech, Inc. | Compositions and methods for activating “stimulator of interferon gene”—dependent signalling |
EP3327004B1 (en) | 2015-07-17 | 2020-11-04 | Fujifilm Corporation | Nitrogen-containing heterocyclic compound |
ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
MA43186B1 (fr) | 2015-11-03 | 2022-03-31 | Janssen Biotech Inc | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
MX2018007423A (es) | 2015-12-17 | 2018-11-09 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas. |
US11345724B2 (en) | 2016-06-06 | 2022-05-31 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Proteasome inhibitors |
CA3026564A1 (en) * | 2016-06-06 | 2017-12-14 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Proteasome inhibitors |
WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
CA3044812A1 (en) | 2016-10-24 | 2018-05-03 | Pellficure Pharmaceuticals Inc. | Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione |
JP6768083B2 (ja) | 2016-12-27 | 2020-10-14 | 富士フイルム株式会社 | 抗腫瘍剤およびブロモドメイン阻害剤 |
CN108264509B (zh) * | 2016-12-30 | 2021-05-04 | 复旦大学 | 取代的苯并噻吩并[2,3-c]四氢吡啶衍生物及其制备方法和用途 |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
EP3679028A1 (en) * | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydroquinolinones |
US11273158B2 (en) | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
CA3092770A1 (en) * | 2018-03-22 | 2019-09-26 | Aurigene Discovery Technologies Limited | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors |
AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
MX2022001450A (es) | 2019-08-08 | 2022-04-20 | Laekna Ltd | Metodo de tratamiento del cancer. |
EP4031578A1 (en) | 2019-09-18 | 2022-07-27 | Novartis AG | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
TW202321210A (zh) * | 2021-07-22 | 2023-06-01 | 瑞士商諾華公司 | 用於治療冠狀病毒相關疾病之化合物及組成物 |
CN115304591A (zh) * | 2022-07-08 | 2022-11-08 | 广州中医药大学(广州中医药研究院) | 一种桥环甾体合成酶抑制剂及其制备方法和应用 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL39283A (en) * | 1971-05-03 | 1976-01-30 | Ciba Geigy Ag | Substituted 2-oxo or thioxo-3-(5-nitro-imidazol-2-yl)-tetrahydroimidazoles and their manufacture |
CH590267A5 (pl) * | 1972-10-04 | 1977-07-29 | Ciba Geigy Ag | |
DE2701794A1 (de) * | 1976-01-21 | 1977-07-28 | Ciba Geigy Ag | Oxigenierte n-aryl-diazacyclen |
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
EP0100172B1 (en) | 1982-07-23 | 1987-08-12 | Imperial Chemical Industries Plc | Amide derivatives |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
NZ224288A (en) | 1987-04-22 | 1989-12-21 | Merrell Dow Pharma | 17b-(cyclopropylamino)androst-5-en-3b-ol and related compounds and methods using these for treatment of non-humans |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
US4966898A (en) | 1989-08-15 | 1990-10-30 | Merrell Dow Pharmaceuticals Inc. | 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors |
US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
AU659632B2 (en) | 1991-03-01 | 1995-05-25 | Electrostatic Technology, Inc. | Powder coating method for producing circuit board laminae and the like |
US5145845A (en) * | 1991-05-14 | 1992-09-08 | Warner-Lambert Co. | Substituted 2-carboxylindoles having pharmaceutical activity |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5457102A (en) | 1994-07-07 | 1995-10-10 | Janssen Pharmaceutica, N.V. | Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives |
ATE186913T1 (de) | 1992-03-31 | 1999-12-15 | Btg Int Ltd | 17-substituierte steroide, verwendbar bei behandlung von krebs |
TW225528B (pl) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
EP1167384B1 (en) | 1992-10-28 | 2006-12-13 | Genentech, Inc. | HVEGF Receptor as Vascular endothelial cell growth factor antagonists |
US5270329A (en) * | 1992-12-10 | 1993-12-14 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
DE4332168A1 (de) * | 1993-02-22 | 1995-03-23 | Thomae Gmbh Dr K | Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
GB9310635D0 (en) | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
JP3916092B2 (ja) * | 1993-09-17 | 2007-05-16 | 杏林製薬株式会社 | イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬 |
WO1995009157A1 (fr) | 1993-09-30 | 1995-04-06 | Yamanouchi Pharmaceutical Co., Ltd. | Derive d'azole et composition pharmaceutique le contenant |
AU676088B2 (en) | 1993-09-30 | 1997-02-27 | British Technology Group Limited | Synthesis of 17-(3-pyridyl) steroids |
WO1996014090A1 (en) | 1994-11-07 | 1996-05-17 | Janssen Pharmaceutica N.V. | Compositions comprising carbazoles and cyclodextrins |
JPH08176111A (ja) * | 1994-12-20 | 1996-07-09 | Kyorin Pharmaceut Co Ltd | N,n′−ジ置換エチレンジアミン誘導体及びそれらを用いたn,n′−ジ置換イミダゾリジノン誘導体の製造方法 |
DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
AU6015796A (en) | 1995-06-14 | 1997-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Fused imidazole derivatives and medicinal composition thereof |
CA2224435C (en) | 1995-07-06 | 2008-08-05 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
AU1592697A (en) | 1995-08-22 | 1997-03-19 | Du Pont Merck Pharmaceutical Company, The | Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
JP3370340B2 (ja) | 1996-04-12 | 2003-01-27 | ワーナー―ランバート・コンパニー | チロシンキナーゼの不可逆的阻害剤 |
AU710926B2 (en) * | 1996-05-20 | 1999-09-30 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
BR9709959A (pt) | 1996-06-24 | 2000-05-09 | Pfizer | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas |
WO1998008849A1 (de) | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
CA2264908C (en) | 1996-09-06 | 2006-04-25 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
DK1367057T3 (da) | 1996-11-18 | 2009-01-19 | Biotechnolog Forschung Gmbh | Epothiloner E og F |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
EP1028110B1 (en) | 1997-10-02 | 2004-04-14 | Daiichi Pharmaceutical Co., Ltd. | Novel dihydronaphthalene compounds and process for producing the same |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
MXPA00008365A (es) | 1998-02-25 | 2002-11-07 | Sloan Kettering Inst Cancer | Sintesis de epotilonas, intermediarios y analogos de las mismas. |
WO1999054309A1 (en) | 1998-04-23 | 1999-10-28 | Takeda Chemical Industries, Ltd. | Naphthalene derivatives, their production and use |
DE69942097D1 (de) | 1998-08-11 | 2010-04-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
NZ511722A (en) | 1998-11-20 | 2004-05-28 | Kosan Biosciences Inc | Recombinant methods and materials for producing epothilone and epothilone derivatives |
IL143596A0 (en) | 1998-12-22 | 2002-04-21 | Genentech Inc | Vascular endothelial cell growth factor antagonists and uses thereof |
ATE329596T1 (de) | 1999-03-30 | 2006-07-15 | Novartis Pharma Gmbh | Phthalazinderivate zur behandlung von entzündlicher erkrankungen |
CA2396596A1 (en) | 2000-01-28 | 2001-08-02 | Bristol-Myers Squibb Company | Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
JP2002302488A (ja) * | 2000-03-30 | 2002-10-18 | Takeda Chem Ind Ltd | 置換1,3−チアゾール化合物、その製造法および用途 |
NO312876B1 (no) * | 2000-07-21 | 2002-07-15 | Balans Man As | Regulerbar stol |
AU2001288605A1 (en) | 2000-09-06 | 2002-03-22 | Chugai Seiyaku Kabushiki Kaisha | A traceless solid-phase synthesis of 2-imidazolones |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
US20040198773A1 (en) | 2001-09-26 | 2004-10-07 | Barry Hart | Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors |
GB0200283D0 (en) | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
EP1542667B1 (en) * | 2002-07-24 | 2012-03-07 | PTC Therapeutics, Inc. | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
CA2498047C (en) | 2002-09-18 | 2009-05-19 | Pfizer Products Inc. | Novel imidazole compounds as transforming growth factor (tgf) inhibitors |
GB0418900D0 (en) | 2004-08-24 | 2004-09-29 | Btg Int Ltd | Novel salt forms |
WO2006078698A1 (en) | 2005-01-19 | 2006-07-27 | Cengent Therapeutics, Inc. | 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases |
KR101380959B1 (ko) | 2005-03-02 | 2014-04-04 | 유니버시티 오브 매릴랜드, 발티모어 | 신규 c-17-헤테로아릴 스테로이드성 cyp17억제제/항안드로겐:합성, 시험관내 생물학적 활성,약물동태학 및 항종양 활성 |
EP1864971A4 (en) * | 2005-03-31 | 2010-02-10 | Takeda Pharmaceutical | PROPHYLACTIC / THERAPEUTIC AGENT AGAINST DIABETES |
US7790707B2 (en) | 2006-03-21 | 2010-09-07 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
AU2007287099A1 (en) | 2006-08-25 | 2008-02-28 | Cougar Biotechnology, Inc. | Methods for treating cancer comprising the administration of a vitamin D compound and an additional therapeutic agent, and compositions containing the same |
WO2008044700A1 (fr) * | 2006-10-11 | 2008-04-17 | Takeda Pharmaceutical Company Limited | INHIBITEUR DE LA GSK-3β |
US20100035918A1 (en) | 2007-01-30 | 2010-02-11 | Biogen Idec Ma Inc | Imidazolone Compounds and Methods of Making and Using the Same |
WO2008154382A1 (en) | 2007-06-06 | 2008-12-18 | University Of Maryland, Baltimore | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
CN101084881B (zh) | 2007-06-23 | 2012-08-29 | 淮北辉克药业有限公司 | 靶向速释泡腾制剂及其制备方法 |
WO2009078992A1 (en) * | 2007-12-17 | 2009-06-25 | Amgen Inc. | Linear tricyclic compounds as p38 kinase inhibitors |
ES2390004T3 (es) * | 2008-01-30 | 2012-11-05 | Cephalon, Inc. | Derivados sustituidos de piperidina espirocíclica como ligandos del receptor de la histamina 3(H3) |
EP2300435A2 (en) * | 2008-05-19 | 2011-03-30 | Schering Corporation | Heterocyclic compounds as factor ixa inhibitors |
CA2729259A1 (en) | 2008-06-25 | 2009-12-30 | Envivo Pharmaceuticals, Inc. | 1,2-disubstituted heterocyclic compounds |
CA2729327C (en) | 2008-06-27 | 2016-10-11 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives that modulate the activity of stearoyl-coa desaturase |
EP2350067A2 (en) | 2008-10-16 | 2011-08-03 | Schering Corporation | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof |
US8431699B2 (en) * | 2009-02-27 | 2013-04-30 | Vertichem Corporation | Method for manufacture of 2-oxoimidazolidines |
WO2011017534A2 (en) | 2009-08-07 | 2011-02-10 | Tokai Pharmaceuticals, Inc. | Treatment of prostate cancer |
US20120282331A1 (en) | 2009-11-13 | 2012-11-08 | Tokai Pharmaceuticals, Inc. | Mammalian metabolites of steroids |
WO2011088160A2 (en) | 2010-01-15 | 2011-07-21 | Biomarin Pharmaceutical Inc. | Novel cyp17 inhibitors |
GB201002563D0 (en) | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
-
2010
- 2010-06-24 SG SG2011084407A patent/SG176105A1/en unknown
- 2010-06-24 MX MX2011013771A patent/MX2011013771A/es active IP Right Grant
- 2010-06-24 EA EA201200049A patent/EA021011B1/ru not_active IP Right Cessation
- 2010-06-24 RS RS20140323A patent/RS53384B/en unknown
- 2010-06-24 ME MEP-2014-65A patent/ME01886B/me unknown
- 2010-06-24 DK DK10730132.7T patent/DK2445903T3/da active
- 2010-06-24 ES ES10730132.7T patent/ES2475945T3/es active Active
- 2010-06-24 AR ARP100102237A patent/AR078228A1/es unknown
- 2010-06-24 BR BRPI1015568A patent/BRPI1015568B8/pt active IP Right Grant
- 2010-06-24 AU AU2010264698A patent/AU2010264698C1/en active Active
- 2010-06-24 GE GEAP201012550A patent/GEP20156250B/en unknown
- 2010-06-24 SI SI201030633T patent/SI2445903T1/sl unknown
- 2010-06-24 UY UY0001032730A patent/UY32730A/es not_active Application Discontinuation
- 2010-06-24 NZ NZ596488A patent/NZ596488A/xx not_active IP Right Cessation
- 2010-06-24 MY MYPI2011005620A patent/MY155570A/en unknown
- 2010-06-24 CA CA2765983A patent/CA2765983C/en active Active
- 2010-06-24 PT PT107301327T patent/PT2445903E/pt unknown
- 2010-06-24 JO JO2010210A patent/JO2892B1/en active
- 2010-06-24 KR KR1020127001913A patent/KR101360725B1/ko active IP Right Grant
- 2010-06-24 EP EP10730132.7A patent/EP2445903B1/en active Active
- 2010-06-24 MA MA34559A patent/MA33451B1/fr unknown
- 2010-06-24 PE PE2011002130A patent/PE20121048A1/es not_active Application Discontinuation
- 2010-06-24 PL PL10730132T patent/PL2445903T3/pl unknown
- 2010-06-24 CN CN201080028351.3A patent/CN102803250B/zh active Active
- 2010-06-24 UA UAA201115301A patent/UA105794C2/uk unknown
- 2010-06-24 JP JP2012516752A patent/JP5456891B2/ja active Active
- 2010-06-24 WO PCT/EP2010/059029 patent/WO2010149755A1/en active Application Filing
- 2010-06-25 TW TW099120966A patent/TWI492942B/zh not_active IP Right Cessation
- 2010-06-28 US US12/824,845 patent/US8263635B2/en not_active Ceased
-
2011
- 2011-11-15 ZA ZA2011/08373A patent/ZA201108373B/en unknown
- 2011-11-29 TN TNP2011000611A patent/TN2011000611A1/en unknown
- 2011-12-01 IL IL216741A patent/IL216741A/en not_active IP Right Cessation
- 2011-12-19 CU CU2011000235A patent/CU24039B1/es active IP Right Grant
- 2011-12-20 CR CR20110684A patent/CR20110684A/es unknown
- 2011-12-21 DO DO2011000399A patent/DOP2011000399A/es unknown
- 2011-12-21 NI NI201100223A patent/NI201100223A/es unknown
- 2011-12-22 CL CL2011003266A patent/CL2011003266A1/es unknown
- 2011-12-22 HN HN2011003371A patent/HN2011003371A/es unknown
- 2011-12-22 CO CO11177195A patent/CO6480927A2/es active IP Right Grant
-
2012
- 2012-01-26 EC EC2012011625A patent/ECSP12011625A/es unknown
- 2012-06-12 HK HK12105692.6A patent/HK1164876A1/xx not_active IP Right Cessation
-
2013
- 2013-06-28 US US13/929,901 patent/USRE45173E1/en active Active
-
2014
- 2014-04-21 US US14/257,433 patent/US20140228394A1/en not_active Abandoned
- 2014-06-24 HR HRP20140593AT patent/HRP20140593T1/hr unknown
- 2014-06-26 CY CY20141100465T patent/CY1115426T1/el unknown
- 2014-07-10 SM SM201400091T patent/SMT201400091B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1164876A1 (en) | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 | |
IL253102A0 (en) | History of hydantoins used as kv3 inhibitors | |
HRP20170279T1 (hr) | Derivati benzimidazola kao inhibitori pi3-kinaze | |
IL254076B (en) | 5-Fluoropyrimidinone derivatives, preparations containing them and methods of using them | |
HK1162022A1 (en) | Picolinamide derivatives as kinase inhibitors | |
HK1164050A1 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
IL207100A0 (en) | 2-amino-quinoline derivatives useful as inhibitors of b-secretase (bace) | |
EP2299824A4 (en) | Pyrazoline Derivatives as FAAH Inhibitors | |
EP2300438A4 (en) | IMIDAZOLE DERIVATIVES AS FAAH INHIBITORS | |
IL212755A0 (en) | Pyrazinopyrazines and derivatives as kinase inhibitors | |
ZA201007431B (en) | Imidazolidinone derivatives as 11b-hsd1 inhibitors | |
PL2297115T3 (pl) | Pochodne di-alkoksychinazolin jako inhibitory receptora KDR | |
EP2320738A4 (en) | SUBSTITUTED AMINOTHIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF | |
EP2432321A4 (en) | THIAZOLOPYRIMIDINONE DERIVATIVES AS INHIBITORS OF PI3 KINASE |